These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

260 related items for PubMed ID: 9574551

  • 1. In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity.
    Toda M, Martuza RL, Kojima H, Rabkin SD.
    J Immunol; 1998 May 01; 160(9):4457-64. PubMed ID: 9574551
    [Abstract] [Full Text] [Related]

  • 2. Combination suicide/cytokine gene therapy as adjuvants to a defective herpes simplex virus-based cancer vaccine.
    Toda M, Martuza RL, Rabkin SD.
    Gene Ther; 2001 Feb 01; 8(4):332-9. PubMed ID: 11313808
    [Abstract] [Full Text] [Related]

  • 3. Immuno-viral therapy of brain tumors by combination of viral therapy with cancer vaccination using a replication-conditional HSV.
    Toda M, Iizuka Y, Kawase T, Uyemura K, Kawakami Y.
    Cancer Gene Ther; 2002 Apr 01; 9(4):356-64. PubMed ID: 11960286
    [Abstract] [Full Text] [Related]

  • 4. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity.
    Todo T, Martuza RL, Dallman MJ, Rabkin SD.
    Cancer Res; 2001 Jan 01; 61(1):153-61. PubMed ID: 11196154
    [Abstract] [Full Text] [Related]

  • 5. Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factor.
    Toda M, Martuza RL, Rabkin SD.
    Mol Ther; 2000 Oct 01; 2(4):324-9. PubMed ID: 11020347
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacy.
    Ino Y, Saeki Y, Fukuhara H, Todo T.
    Clin Cancer Res; 2006 Jan 15; 12(2):643-52. PubMed ID: 16428511
    [Abstract] [Full Text] [Related]

  • 12. Preclinical evaluation of "whole" cell vaccines for prophylaxis and therapy using a disabled infectious single cycle-herpes simplex virus vector to transduce cytokine genes.
    Ali SA, McLean CS, Boursnell ME, Martin G, Holmes CL, Reeder S, Entwisle C, Blakeley DM, Shields JG, Todryk S, Vile R, Robins RA, Rees RC.
    Cancer Res; 2000 Mar 15; 60(6):1663-70. PubMed ID: 10749137
    [Abstract] [Full Text] [Related]

  • 13. Defective herpes simplex virus vectors expressing thymidine kinase for the treatment of malignant glioma.
    Miyatake S, Martuza RL, Rabkin SD.
    Cancer Gene Ther; 1997 Mar 15; 4(4):222-8. PubMed ID: 9253507
    [Abstract] [Full Text] [Related]

  • 14. Therapeutic immune response induced by intratumoral expression of the fusogenic membrane protein of vesicular stomatitis virus and cytokines encoded by adenoviral vectors.
    Hoffmann D, Bayer W, Wildner O.
    Int J Mol Med; 2007 Nov 15; 20(5):673-81. PubMed ID: 17912460
    [Abstract] [Full Text] [Related]

  • 15. Oncolytic recombinant herpes simplex virus for treatment of orthotopic liver tumors in nude mice.
    Chung YS, Miyatake S, Miyamoto A, Miyamoto Y, Dohi T, Tanigawa N.
    Int J Oncol; 2006 Apr 15; 28(4):793-8. PubMed ID: 16525626
    [Abstract] [Full Text] [Related]

  • 16. The role of the E1B 55 kDa gene product in oncolytic adenoviral vectors expressing herpes simplex virus-tk: assessment of antitumor efficacy and toxicity.
    Wildner O, Morris JC.
    Cancer Res; 2000 Aug 01; 60(15):4167-74. PubMed ID: 10945625
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.